Tumor Biology

, Volume 32, Issue 2, pp 295–300 | Cite as

Polymorphisms in the 5′- and 3′-untranslated region of the VEGF gene and sporadic breast cancer risk and clinicopathologic characteristics

  • Cristiane Oliveira
  • Gustavo J. Lourenço
  • Priscilla M. R. Silva
  • Cassio Cardoso-Filho
  • Maira H. C. Favarelli
  • Neiva S. L. Gonçales
  • Maria S. C. Gurgel
  • Carmen S. P. Lima
Research Article


The wild and the variant alleles of the C936T and G634C vascular endothelial grow factor (VEGF) polymorphisms seem to be linked to higher angiogenic phenotype than the remaining alleles and may act on breast cancer (BC) origin. We investigated the influence of the VEGF C936T and G634C polymorphisms on the occurrence and clinicopathologic characteristics of sporadic breast cancer (SBC) in 235 patients and 235 controls. Peripheral blood samples of all individuals were analysed by the polymerase chain reaction for identification of genotypes and by enzyme-linked immunosorbent assay (ELISA) for quantification of serum VEGF levels. The variant 634CC genotype isolated (16.2% versus 10.7%, P= 0.01) and in combination with the wild 936CC genotype (10.6% versus 5.5%, P= 0.01) were more common in patients than in controls. The carriers of the respective genotypes were under a 2.20-fold and a 3.08-fold increased risks for the disease. Additionally, the frequency of the wild 936CC genotype was higher in patients with tumours of histological grade III compared to those with tumours of I+II histological grades (84.0% versus 64.7%, P= 0.004) and in patients with positive oestrogen receptor tumours compared to those with tumours lacking oestrogen receptor expression (84.7% versus 73.9%, P= 0.02). Similar serum values of VEGF were seen in patients and controls with the distinct genotypes of the VEGF. The data suggest that the VEGF wild 936CC and the variant 634CC genotypes constitute inherited determinants of SBC and SBC aggressiveness in Brazil, but are not significant predictors of circulating VEGF levels.


Breast cancer Angiogenesis Polymorphism VEGF Risk 



This work was supported by Fundação à Pesquisa do Estado de São Paulo (FAPESP).

Conflict of interest statement

We declare that we have no conflict of interest.


  1. 1.
    El-Gohary YM, Metwally G, Saad RS, et al. Prognostic significance of intratumoral and peritumoral lymphatic density and blood vessel density in invasive breast carcinomas. Am J Clin Pathol. 2008;8(129):578–86.CrossRefGoogle Scholar
  2. 2.
    Berezov TT, Ovchinnikova LK, Kuznetsova OM, et al. Vascular endothelial growth factor in the serum of breast cancer patients. Bull Exp Biol Med. 2009;148:419–24.CrossRefPubMedGoogle Scholar
  3. 3.
    Hu Z, Fan C, Livasy C, et al. A compact VEGF signature associated with distant metastases and poor outcomes. BMC Med. 2009;16:7–9.Google Scholar
  4. 4.
    Mohammed RA, Ellis IO, Elsheikh S, et al. Lymphatic and angiogenic characteristics in breast cancer: morphometric analysis and prognostic implications. Breast Cancer Res Treat. 2009;113:261–73.CrossRefPubMedGoogle Scholar
  5. 5.
    Shivakumar S, Prabhakar BT, Jayashree K, et al. Evaluation of serum vascular endothelial growth factor (VEGF) and microvessel density (MVD) as prognostic indicators in carcinoma breast. J Cancer Res Clin Oncol. 2009;135:627–36.CrossRefPubMedGoogle Scholar
  6. 6.
    Carpini JD, Karam AK, Montgomery L. Vascular endothelial growth factor and its relationship to the prognosis and treatment of breast, ovarian, and cervical cancer. Angiogenesis. 2010;13:43–58.CrossRefPubMedGoogle Scholar
  7. 7.
    Safali M, Karslioğlu Y, Arpaci F, et al. A distinct microvascular pattern accompanied by aggressive clinical course in breast carcinomas: a fact or a coincidence? Pathol Res Pract. 2010;206:93–7.CrossRefPubMedGoogle Scholar
  8. 8.
    Renner W, Kotschan S, Hoffman C, et al. A common 936C/T mutation in the gene for vascular endothelial growth factor plasma levels. J Vasc Res. 2009;37:443–8.CrossRefGoogle Scholar
  9. 9.
    Krippl P, Langsenlehner V, Renner W, et al. A common 936C/T gene polymorphism of vascular endothelial growth factor is associated with decrease breast cancer risk. Int J Cancer. 2003;106:469–71.CrossRefGoogle Scholar
  10. 10.
    Jakubowska A, Gronwald J, Menkiszak J, et al. The VEGF_936_C>T 3′UTR polymorphism reduces BRCA1-associated breast cancer risk in Polish women. Cancer Lett. 2008;262:71–6.CrossRefGoogle Scholar
  11. 11.
    Balasubramanian SP, Cox A, Cross SS, et al. Influence of VEGF-A gene variation and protein levels in breast cancer susceptibility and severity. Int J Cancer. 2007;121:1009–16.CrossRefPubMedGoogle Scholar
  12. 12.
    Langsenlehner U, Wolf G, Langsenlehner T, et al. Genetic polymorphisms in the vascular endothelial growth factor gene and breast cancer risk. The Austrian “tumor of breast tissue: incidence, genetics, and environmental risk factors” study. Breast Cancer Res Treat. 2008;109:297–304.CrossRefPubMedGoogle Scholar
  13. 13.
    Jin Q, Hemminki K, Enquist K, et al. Vascular endothelial growth factor polymorphism in relation to breast cancer development and prognosis. Clin Cancer Res. 2005;11:3647–53.CrossRefPubMedGoogle Scholar
  14. 14.
    Jacobs EJ, Feigelson HS, Bain EB, et al. Polymorphisms in the vascular endothelial growth factor gene and breast cancer in the Cancer Prevention Study II cohort. Breast Cancer Res. 2006;8:R22–7.CrossRefPubMedGoogle Scholar
  15. 15.
    Kataoka N, Cai Q, Wen W, et al. Population-based case-control study of VEGF gene polymorphism and breast cancer risk among Chinese women. Cancer Epidemiol Biomark Prev. 2006;15:1148–52.CrossRefGoogle Scholar
  16. 16.
    Schneider BP, Radovich M, Sledge GW, et al. Association of polymorphisms of angiogenesis genes with breast cancer. Breast Cancer Res Treat. 2008;111:157–63.CrossRefPubMedGoogle Scholar
  17. 17.
    Gu D, Wang M (2010) VEGF 936C>T polymorphism and breast cancer risk: evidence from 5,729 cases and 5,868 controls. Breast Cancer Res Treat 19. doi: 10.1007/s10549-010-0991-z
  18. 18.
    Xu B, Li JM, Tong N, et al. VEGFA +936C>T polymorphism and cancer risk: a meta-analysis. Cancer Genet Cytogenet. 2010;198:7–14.CrossRefPubMedGoogle Scholar
  19. 19.
    Eroglu A, Oztürk A, Cam R, et al. Vascular endothelial growth factor gene 936C/T polymorphism in breast cancer patients. Med Oncol. 2005;25:54–5.CrossRefGoogle Scholar
  20. 20.
    Lin GT, Tseng HF, Yang CH, et al. Combinational polymorphisms of seven CXCL12-related genes are protective against breast cancer in Taiwan. OMICS. 2009;13:165–72.CrossRefPubMedGoogle Scholar
  21. 21.
    Watson CJ, Webb NJ, Bottomley MJ, et al. Identification of polymorphisms within the vascular endothelial growth factor (VEGF) gene: correlation with variation in VEGF protein production. Cytokine. 2000;12:1232–5.CrossRefPubMedGoogle Scholar
  22. 22.
    Awata T, Inoue K, Kurihara S, et al. A common polymorphism in the 5′-untranslated region of the VEGF gene is associated with diabetic retinopathy in the type 2 diabetes. Diabetes. 2002;51:1635–9.CrossRefPubMedGoogle Scholar
  23. 23.
    Brasil. Instituto Nacional de Câncer. Incidência de Câncer no Brasil. Estimativa 2010. Publishing Ministério da Saúde
  24. 24.
    Muniz JJ, Izidoro-Toledo TC, Metzger IF, et al. Interethnic differences in the distribution of clinically relevant vascular endothelial growth factor genetic polymorphisms. DNA Cell Biol. 2009;28:567–72.CrossRefPubMedGoogle Scholar
  25. 25.
    Alves-Silva J, Da Silva-Santos M, Guimarães, et al. The ancestry of Brazilian mtDNA lineages. Am J Hum Genet. 2009;67:444–61.CrossRefGoogle Scholar
  26. 26.
    Carvalho-Silva DR, Santos FR, Rocha J, et al. The phylogeography of Brazilian Y-chromosome lineages. Am J Hum Genet. 2001;68:281–6.CrossRefPubMedGoogle Scholar
  27. 27.
    Yang DS, Park KH, Woo OH, Woo SU et al (2010) Association of a vascular endothelial growth factor gene 936C/T polymorphism with breast cancer risk: a meta-analysis. Breast Cancer Res Treat 21. doi: 10.1007/s10549-010-1070-1
  28. 28.
    Elston CW, Ellis IO. Pathological prognostic factors in breast cancer. The value of histological grade in breast cancer: experience from a large study with long-term follow-up. Histopathology. 1991;19:403–10.CrossRefPubMedGoogle Scholar
  29. 29.
    Greene FL, Page DL, Fleming ID, et al. Breast. In: Balch CM, editor. AJCC Cancer staging manual. 6th ed. New York: Springer; 2002. p. 223–40.Google Scholar
  30. 30.
    Papazoglou D, Galazios G, Koukourakis MI, et al. Vascular endothelial growth factor gene polymorphisms and pre-eclampsia. Mol Hum Reprod. 2000;10:321–4.CrossRefGoogle Scholar
  31. 31.
    Losordo DW, Isner JM. Estrogen and angiogenesis: a review. Arterioscler Thromb Vasc Biol. 2001;21:6–12.PubMedGoogle Scholar

Copyright information

© International Society of Oncology and BioMarkers (ISOBM) 2010

Authors and Affiliations

  • Cristiane Oliveira
    • 1
  • Gustavo J. Lourenço
    • 1
  • Priscilla M. R. Silva
    • 1
  • Cassio Cardoso-Filho
    • 2
  • Maira H. C. Favarelli
    • 3
  • Neiva S. L. Gonçales
    • 3
  • Maria S. C. Gurgel
    • 2
  • Carmen S. P. Lima
    • 1
  1. 1.Department of Internal Medicine, Faculty of Medical SciencesState University of CampinasCampinasBrazil
  2. 2.Department of Obstetrics and Gynaecology, Faculty of Medical SciencesState University of CampinasCampinasBrazil
  3. 3.Haematology and Haemotherapy Centre, Faculty of Medical SciencesState University of CampinasCampinasBrazil

Personalised recommendations